NCT02564497View on ClinicalTrials.gov

A Study to Compare the Pharmacokinetics of Belatacept Using Active Pharmaceutical Ingredient Manufactured by Process E Relative to Process C

PHASE1CompletedINTERVENTIONAL
Enrollment

491

Participants

Timeline

Start Date

October 2, 2015

Primary Completion Date

January 27, 2017

Study Completion Date

January 27, 2017

Conditions
Renal Transplantation
Interventions
BIOLOGICAL

Process E Belatacept

BIOLOGICAL

Process C Belatacept

Trial Locations (1)

Unknown

PPD Development, Austin

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY